GO:0030193 regulation of blood coagulation: Hemostasis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030193 (regulation of blood coagulation) describes any process that modulates the frequency, rate or extent of blood coagulation, the enzymatic conversion of fluid blood into a fibrin clot.
• Coagulation is controlled by a balance between procoagulant serine proteases (thrombin, FXa, FVIIa) and anticoagulant pathways, chiefly the protein C system, antithrombin and tissue factor pathway inhibitor.
• Platelets, the vessel wall, blood flow and mass transfer of coagulation factors all modulate the reaction kinetics of clot formation.
• Genetic lesions in anticoagulant regulators such as PROC, PROS1, SERPINC1 and F5 cause thrombotic or bleeding phenotypes, making this GO term central to cardiovascular genetics.
• CRISPR knockout, point-mutation, knock-in and overexpression cell models allow causal testing of candidate regulators of blood coagulation in a defined genetic background.
• The term is a biological_process node, so it is studied with coagulation assays, thrombin-generation tests, flow models, proteomics and CRISPR screens rather than with a single molecular readout.
Description
GO:0030193, regulation of blood coagulation, is a Gene Ontology biological_process term defined as any process that modulates the frequency, rate or extent of blood coagulation. Blood coagulation itself is the cascade of serine-protease activation events that converts soluble fibrinogen into an insoluble fibrin network, and its regulation determines whether a clot forms at the right place, at the right time and for the right duration. Because both excessive and insufficient clotting cause disease, the regulators annotated to this term are among the most intensively studied proteins in hemostasis research. Mechanistically, regulation of blood coagulation is not a single reaction but a network of positive and negative feedback loops. Procoagulant initiators such as tissue factor and activated platelets drive thrombin generation, while the protein C anticoagulant pathway, antithrombin and tissue factor pathway inhibitor restrain it. Platelets contribute both membrane surfaces for assembly of tenase and prothrombinase complexes and secreted modulators that shape clot size and stability. Blood flow and mass transfer further regulate the local concentration of factors and inhibitors, so the process is inherently spatial and dynamic. For researchers, GO:0030193 provides a controlled vocabulary for annotating genes whose products tune coagulation rather than execute it. This distinction matters when interpreting CRISPR screens, transcriptomic signatures and patient variants, because loss of a regulator can shift the system toward thrombosis or bleeding without abolishing the core cascade. The sections below summarize the ontology definition, the major stages, the key genes and the experimental models used to study this term.
regulation of blood coagulation At A Glance
| GO ID | GO:0030193 |
|---|---|
| GO term | regulation of blood coagulation |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Definition | Any process that modulates the frequency, rate or extent of blood coagulation. |
| Major function | Balancing procoagulant and anticoagulant reactions so that clot formation is spatially and temporally controlled |
| Key pathways | Protein C anticoagulant pathway, antithrombin and tissue factor pathway inhibitor, platelet-coagulation interplay |
| Representative regulators | PROC, PROS1, SERPINC1, F5, F2, F10, TFPI, PLAT, PLAU, THBD |
| Disease relevance | Venous thrombosis, bleeding disorders, disseminated intravascular coagulation and cardiovascular disease |
What Is GO:0030193?
In this article, regulation of blood coagulation (GO:0030193) means any biological process that changes how often, how fast or how far blood coagulation proceeds. It is a parent-level regulatory term: the gene products annotated to it do not necessarily form the fibrin clot themselves, but they modulate the activity, availability or assembly of the coagulation machinery. Examples include activation or inhibition of coagulation proteases, control of cofactor exposure on platelet and endothelial membranes, and feedback loops that terminate thrombin generation.
Why Is regulation of blood coagulation Important in Cell Biology?
Regulation of blood coagulation is important because the same enzymatic cascade that prevents fatal hemorrhage can, when dysregulated, occlude vessels and cause myocardial infarction, stroke or venous thromboembolism. The protein C anticoagulant pathway is a textbook example: loss-of-function variants in PROC or PROS1, or the factor V Leiden mutation that impairs activated protein C cleavage, shift the balance toward thrombosis. Conversely, impaired procoagulant regulation causes bleeding. Because the term captures the modulatory layer rather than the core cascade, it is the natural annotation target for genes identified in CRISPR screens, genome-wide association studies and platelet biology studies.
• Defines the mechanistic balance between clot formation and clot prevention in vivo.
• Provides the ontology framework for annotating anticoagulant genes such as PROC, PROS1 and SERPINC1.
• Explains the genetic basis of thrombophilia, including factor V Leiden and protein C or protein S deficiency.
• Links platelet biology to coagulation, since platelets supply membranes and secreted regulators.
• Incorporates biophysical regulation by blood flow and mass transfer of coagulation factors.
• Supports interpretation of neutrophil extracellular trap and complement crosstalk with coagulation.
• Guides anticoagulant drug target selection, including thrombin and factor Xa inhibitors.
• Enables functional genomics screens that separate causal regulators from bystander coagulation genes.
What Happens During regulation of blood coagulation?
Initiation and amplification of thrombin generation
In simple terms: Clotting starts when injury exposes tissue factor, and this small spark is amplified into a burst of thrombin.
Coagulation is initiated when tissue factor exposed at the site of vessel injury binds factor VIIa and activates factor X and factor IX, generating small amounts of thrombin. This initial thrombin activates platelets and cofactors, creating a positive feedback loop that amplifies thrombin generation on platelet and endothelial membranes. Regulation at this stage determines whether the spark remains local or propagates into a systemic prothrombotic state.
Anticoagulant restraint by the protein C pathway
In simple terms: The protein C pathway is the brake that stops thrombin from overrunning the system.
Thrombin bound to thrombomodulin activates protein C, which with its cofactor protein S cleaves and inactivates factors Va and VIIIa, thereby downregulating thrombin generation. This pathway is a canonical example of regulation of blood coagulation because it does not create or destroy the cascade but modulates its rate and extent. Genetic defects in this pathway are established causes of thrombotic disease.
Serine protease inhibitors and tissue factor pathway inhibitor
In simple terms: Inhibitors act as molecular sponges that soak up activated clotting enzymes.
Antithrombin neutralizes thrombin and factor Xa, and its activity is enhanced by heparan sulfate proteoglycans on the vessel wall. Tissue factor pathway inhibitor complexes with factor Xa to shut down the tissue factor-factor VIIa initiation complex, providing a second layer of negative regulation. Together these inhibitors set the threshold below which coagulation does not propagate.
Platelet-coagulation interplay
In simple terms: Platelets are both the stage and the actors: they provide surfaces for clotting reactions and release signals that tune them.
Activated platelets expose phosphatidylserine, assemble tenase and prothrombinase complexes, and release granule contents that modulate coagulation and fibrinolysis. Platelet-derived polyphosphates and microparticles further influence thrombin generation and clot stability. This interplay means that regulation of blood coagulation cannot be modeled by plasma biochemistry alone.
Biophysical regulation by flow and mass transfer
In simple terms: Blood flow delivers factors and washes away inhibitors, so the speed of flow changes how fast clots grow.
Blood flow controls the local concentration of coagulation factors, inhibitors and platelets at the injured surface, and mass transfer limitations shape reaction rates. Under low shear, thrombin accumulates and clot growth is favored, whereas high shear can dilute reactants and limit propagation. Computational and microfluidic models are therefore used to study regulation of blood coagulation under physiologically relevant flow.
Crosstalk with inflammation and innate immunity
In simple terms: Immune cells and clotting proteins talk to each other, so inflammation can push coagulation up or down.
Neutrophil extracellular traps and complement proteins such as C1q interact with procoagulant and anticoagulant factors, modifying the net coagulation response. This crosstalk helps explain why infection and inflammation are associated with both thrombosis and bleeding. It also expands the set of genes that can be annotated to regulation of blood coagulation beyond classical hemostasis factors.
Key Genes Involved in GO:0030193 regulation of blood coagulation
The following genes encode proteins that have been experimentally linked to regulation of blood coagulation, either as procoagulant drivers, anticoagulant brakes or modulators of the reaction environment.
| Gene | Major Role | Research Relevance |
|---|---|---|
| F2 | Encodes prothrombin, the zymogen of thrombin, the central protease of coagulation | Core target for anticoagulant studies and thrombin-generation assays |
| F5 | Encodes factor V, a procoagulant cofactor that is inactivated by activated protein C | Factor V Leiden is a classic thrombophilia variant studied by point mutation |
| F10 | Encodes factor X, which assembles into the prothrombinase complex | Target of direct oral anticoagulants and of CRISPR knockout studies |
| PROC | Encodes protein C, the zymogen of the anticoagulant protease activated protein C | Loss-of-function variants cause protein C deficiency and thrombosis |
| PROS1 | Encodes protein S, the cofactor for activated protein C | Protein S deficiency is a hereditary thrombophilia |
| SERPINC1 | Encodes antithrombin, the major plasma inhibitor of thrombin and factor Xa | Antithrombin deficiency is a strong risk factor for venous thrombosis |
| TFPI | Encodes tissue factor pathway inhibitor, which blocks the initiation complex | Modulates the threshold of coagulation initiation |
| THBD | Encodes thrombomodulin, the endothelial receptor that activates protein C | Central to the protein C anticoagulant pathway |
| F7 | Encodes factor VII, the protease that initiates tissue factor-dependent coagulation | Relevant to initiation-phase regulation and bleeding phenotypes |
| F8 | Encodes factor VIII, the cofactor for factor IXa that is inactivated by activated protein C | Hemophilia A and thrombophilia research model |
| F9 | Encodes factor IX, the protease of the tenase complex | Hemophilia B and coagulation cascade studies |
| PLAT | Encodes tissue-type plasminogen activator, linking coagulation to fibrinolysis | Used to study clot resolution and balance with coagulation |
| PLAU | Encodes urokinase plasminogen activator, a modulator of pericellular proteolysis | Relevant to clot remodeling and cell-surface coagulation |
| SERPINE1 | Encodes plasminogen activator inhibitor-1, which restrains fibrinolysis | Candidate modifier of clot persistence |
| VWF | Encodes von Willebrand factor, which mediates platelet adhesion and carries factor VIII | Links platelet function to coagulation regulation |
| GP6 | Encodes glycoprotein VI, a platelet collagen receptor | Platelet-side regulator of thrombus formation |
| ITGA2B | Encodes integrin alpha-IIb, required for platelet aggregation | Target for antiplatelet and coagulation crosstalk studies |
| C1QA | Encodes complement C1q, implicated in C1q-NET-driven coagulation crosstalk | Emerging link between innate immunity and coagulation |
How Is regulation of blood coagulation Regulated?
Regulation of blood coagulation is itself regulated at multiple levels. Transcriptionally, inflammatory cytokines and hypoxia can alter the expression of tissue factor, thrombomodulin and plasminogen activator inhibitor-1, shifting the balance between procoagulant and anticoagulant states. Post-translationally, gamma-carboxylation of vitamin K-dependent factors is required for their membrane binding and activity, and this modification is a regulated step in coagulation competence. Feedback regulation by thrombin is central: thrombin activates platelets and cofactors but also, via thrombomodulin, activates protein C to terminate its own generation. In addition, blood flow and mass transfer continuously modulate local factor concentrations, effectively acting as a physical regulator of the process. Finally, crosstalk with neutrophils and complement can either amplify or restrain coagulation depending on context.
regulation of blood coagulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PROC | Protein C deficiency and venous thrombosis | CRISPR knockout or point-mutation in hepatic cell lines followed by thrombin-generation assays |
| PROS1 | Protein S deficiency and thrombophilia | Knockout and rescue with wild-type or variant PROS1 |
| F5 | Factor V Leiden and activated protein C resistance | Point-mutation knock-in of the Leiden allele in a coagulation-competent cell model |
| SERPINC1 | Antithrombin deficiency and thrombosis | Knockout in hepatocyte-like cells and measurement of thrombin inhibition |
| THBD | Endothelial anticoagulant dysfunction | Endothelial cell knockout and protein C activation assays |
Thrombophilia and venous thromboembolism
Defects in the anticoagulant regulators annotated to GO:0030193 are established causes of inherited thrombophilia. Protein C and protein S deficiency, antithrombin deficiency and the factor V Leiden mutation all impair the protein C anticoagulant pathway and increase the risk of venous thromboembolism. These genotypes illustrate how loss of regulatory function, rather than gain of clotting activity, can produce a prothrombotic state.
Bleeding disorders and impaired hemostasis
Conversely, excessive restraint of coagulation or loss of procoagulant amplification causes bleeding. Deficiencies of factors VIII and IX cause hemophilia A and B, and defects in platelet-coagulation interplay can produce mucocutaneous bleeding. Studying regulation of blood coagulation therefore requires attention to both directions of dysregulation.
Inflammation-associated coagulopathy
Sepsis and systemic inflammation can drive disseminated intravascular coagulation, in which widespread activation of coagulation consumes factors and paradoxically causes bleeding. Neutrophil extracellular traps and complement components such as C1q participate in this crosstalk, linking innate immunity to regulation of blood coagulation. This has motivated research into anti-inflammatory strategies that indirectly modulate coagulation.
Cardiovascular and cancer-associated thrombosis
Atherosclerosis, myocardial infarction and cancer-associated thrombosis all involve dysregulated coagulation and platelet activation. Tumor cells and their microvesicles can express tissue factor and other procoagulant activities, shifting the balance toward thrombosis. Genes annotated to GO:0030193 are therefore candidate modifiers in cardio-oncology and vascular biology.
From regulation of blood coagulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate anticoagulant gene increase thrombin generation? | CRISPR knockout in hepatic or endothelial cells with thrombin-generation assay |
| Does a patient variant impair activated protein C cleavage of factor V? | Point-mutation knock-in of the variant allele and cleavage assay |
| Can a tagged regulator be tracked in live cells? | Tagged knock-in with fluorescent or affinity tag and imaging |
| Does overexpression of an inhibitor suppress coagulation? | Stable overexpression in a coagulation-competent cell line |
| Which genes causally regulate clot formation in a pooled format? | CRISPR library screening with a coagulation or thrombin readout |
| How does flow affect the regulatory balance? | Microfluidic endothelial model under defined shear |
How to Study the regulation of blood coagulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Thrombin-generation assay | Rate and peak of thrombin production | Functional validation of anticoagulant gene knockouts |
| Prothrombin time / aPTT | Global clotting time of plasma | Screening for procoagulant or anticoagulant shifts |
| CRISPR knockout screen | Genes whose loss changes a coagulation readout | Discovery of novel regulators of blood coagulation |
| Point-mutation knock-in | Effect of a specific patient variant | Modeling factor V Leiden or protein C variants |
| Overexpression | Consequence of excess regulator | Testing inhibitor gain-of-function |
| Proteomics | Abundance and modification of coagulation proteins | Mechanistic follow-up of screen hits |
| Microfluidic flow assay | Clot formation under shear | Physiological modeling of regulation |
| Platelet aggregation assay | Platelet-coagulation interplay | Testing platelet-side regulators |
Coagulation and thrombin-generation assays
Global clotting tests such as prothrombin time and activated partial thromboplastin time, together with calibrated automated thrombography, measure the rate and extent of thrombin generation in plasma or cell-conditioned medium. These assays are the primary functional readout for genes annotated to regulation of blood coagulation.
CRISPR functional genomics
Pooled CRISPR knockout and activation screens can identify regulators that change thrombin generation, platelet activation or clot formation in a defined cell background. Hits are then validated individually with clonal knockout or point-mutation lines.
Proteomics and activity-based profiling
Mass spectrometry-based proteomics and activity-based probes can quantify coagulation factors and their activation states in conditioned media or plasma. This helps distinguish changes in protein abundance from changes in enzymatic activity.
Microfluidics and imaging under flow
Microfluidic devices that perfuse blood or plasma over endothelial and platelet surfaces allow regulation of blood coagulation to be studied under controlled shear and mass-transfer conditions. Fluorescence imaging of fibrin and platelet deposition provides spatial information that static assays cannot capture.
How CRISPR Can Be Used to Study GO:0030193 regulation of blood coagulation
Knockout
CRISPR knockout of a candidate regulator such as PROC, PROS1 or SERPINC1 removes the gene product and allows the resulting shift in thrombin generation to be measured directly. Knockout is the most straightforward way to test whether a gene is required for normal regulation of blood coagulation.
Point Mutation
Point-mutation knock-in can recreate patient variants, such as factor V Leiden, in a controlled cell background so that the specific effect on activated protein C cleavage can be quantified. This approach separates the contribution of a single amino acid change from background genetic variation.
Knock-in
Knock-in of tags or reporter cassettes enables tracking of regulator expression, localization and secretion without altering the endogenous locus. Tagged knock-in lines are useful for imaging platelet and endothelial contributions to coagulation regulation.
Overexpression
Overexpression of an anticoagulant or procoagulant regulator tests gain-of-function effects on clot formation and can reveal dose-sensitive regulation. It complements knockout by probing the opposite direction of the regulatory balance.
How EDITGENE Supports regulation of blood coagulation Research
Researchers studying regulation of blood coagulation-related genes often need to determine whether a candidate gene is causally involved in modulating clot formation or is merely correlated with a disease phenotype. Establishing causality requires controlled genetic perturbation in a relevant cell background, followed by functional coagulation assays. EDITGENE provides the CRISPR tools and cell models needed to move from candidate gene to mechanistic evidence.
Contact EDITGENE today to design your custom CRISPR model for regulation of blood coagulation research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| F2RL1 Knockout HEK293T Cell Line | EDJ-KQ222 | Human | 2150 | Details Get a Quote |
| F2R Knockout HEK293 Cell Line | EDJ-KQ793 | Human | 2149 | Details Get a Quote |
| CAV1 Knockout HEK293 Cell Line | EDJ-KQ977 | Human | 857 | Details Get a Quote |
| F2 Knockout HEK293 Cell Line | EDJ-KQ1714 | Human | 2147 | Details Get a Quote |
| EPHB2 Knockout HEK293 Cell Line | EDJ-KQ2329 | Human | 2048 | Details Get a Quote |
| HRG Knockout HEK293 Cell Line | EDJ-KQ2350 | Human | 3273 | Details Get a Quote |
| FOXA2 Knockout HEK293 Cell Line | EDJ-KQ2898 | Human | 3170 | Details Get a Quote |
| SERPINC1 Knockout HEK293 Cell Line | EDJ-KQ3533 | Human | 462 | Details Get a Quote |
| F2RL1 Knockout HEK293 Cell Line | EDJ-KQ17871 | Human | 2150 | Details Get a Quote |
| CAV1 Knockout A-549 Cell Line | EDJ-KQ19995 | Human | 857 | Details Get a Quote |
| CAV1 Knockout HCT 116 Cell Line | EDJ-KQ19996 | Human | 857 | Details Get a Quote |
| CAV1 Knockout HeLa Cell Line | EDJ-KQ19997 | Human | 857 | Details Get a Quote |
| F2RL1 Knockout HCT 116 Cell Line | EDJ-KQ25963 | Human | 2150 | Details Get a Quote |
| F2R Knockout A-549 Cell Line | EDJ-KQ18282 | Human | 2149 | Details Get a Quote |
| F2R Knockout HCT 116 Cell Line | EDJ-KQ19509 | Human | 2149 | Details Get a Quote |
Displaying Records 1 To 15 Of 42 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About regulation of blood coagulation
What is GO:0030193 regulation of blood coagulation?
GO:0030193 is a Gene Ontology biological_process term defined as any process that modulates the frequency, rate or extent of blood coagulation. It covers the regulatory layer that tunes clot formation rather than the core fibrin-forming reactions themselves.
What genes are involved in regulation of blood coagulation?
Key genes include PROC and PROS1 of the protein C pathway, SERPINC1 encoding antithrombin, TFPI, THBD, F2, F5, F10, F7, F8, F9, VWF and platelet receptors such as GP6.
How is blood coagulation regulated?
Coagulation is regulated by the protein C anticoagulant pathway, serine protease inhibitors such as antithrombin, tissue factor pathway inhibitor, platelet-coagulation interplay, blood flow and mass transfer, and crosstalk with inflammation.
What is the protein C anticoagulant pathway?
It is a feedback system in which thrombin bound to thrombomodulin activates protein C; activated protein C with protein S then cleaves factors Va and VIIIa to downregulate thrombin generation.
Which diseases are linked to defective regulation of blood coagulation?
Protein C and protein S deficiency, antithrombin deficiency and factor V Leiden cause thrombophilia and venous thromboembolism, while other defects cause bleeding or disseminated intravascular coagulation.
How do platelets regulate blood coagulation?
Activated platelets expose phosphatidylserine, assemble tenase and prothrombinase complexes, and release granule contents that modulate thrombin generation and clot stability.
How can CRISPR be used to study regulation of blood coagulation?
CRISPR knockout, point-mutation knock-in, tagged knock-in and overexpression models allow causal testing of candidate regulators in coagulation-competent cells, followed by thrombin-generation assays.
What assays measure regulation of blood coagulation?
Thrombin-generation assays, prothrombin time, activated partial thromboplastin time, platelet aggregation, proteomics and microfluidic flow assays are commonly used.
Does blood flow affect coagulation regulation?
Yes, blood flow and mass transfer control local concentrations of coagulation factors and inhibitors and therefore shape reaction rates and clot growth.
Why is regulation of blood coagulation important for drug discovery?
Because both excessive and insufficient clotting cause disease, regulators such as thrombin, factor Xa and the protein C pathway are validated drug targets and guide anticoagulant development.
Conclusion
GO:0030193 regulation of blood coagulation captures the modulatory network that keeps clot formation spatially and temporally controlled. Its core components include the protein C anticoagulant pathway, serine protease inhibitors, platelet-coagulation interplay and biophysical regulation by flow, all of which have been linked to thrombotic and bleeding disorders. Understanding this term at the gene level requires functional perturbation rather than correlation alone. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with thrombin-generation assays and CRISPR screening, provide a direct route from candidate gene to causal mechanism. Researchers can use these approaches to dissect how individual regulators shift the coagulation balance and to prioritize targets for anticoagulant or hemostatic intervention.
References
- 1. Esmon CT. 2000. Regulation of blood coagulation.. Biochim Biophys Acta 1477(1-2):349-60 PMID: 10708869
- 2. Sang Y et al.. 2021. Interplay between platelets and coagulation.. Blood Rev 46:100733 PMID: 32682574
- 3. Walker FJ et al.. 1992. Regulation of blood coagulation by the protein C system.. FASEB J 6(8):2561-7 PMID: 1317308
- 4. Thomas M et al.. 2025. Interplay of procoagulatory and neutrophil-derived anticoagulatory proteins in C1q-NET-driven blood coagulation.. Blood 146(24):2993-3002 PMID: 40997304
- 5. Versteeg HH et al.. 2013. New fundamentals in hemostasis.. Physiol Rev 93(1):327-58 PMID: 23303912
- 6. Rana K et al.. 2016. Blood flow and mass transfer regulation of coagulation.. Blood Rev 30(5):357-68 PMID: 27133256
- 7. Dahlbäck B et al.. 2005. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition.. Arterioscler Thromb Vasc Biol 25(7):1311-20 PMID: 15860736
- 8. Dahlbäck B. 2005. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases.. J Intern Med 257(3):209-23 PMID: 15715678
